Table 3.
Univariate and multivariate analyses of the associations between clinicopathological parameters and overall survival using logistic regression model
| Univariate |
p-value | Multivariate |
p-value | ||
|---|---|---|---|---|---|
| RR (95% CI) | RR (95% CI) | ||||
| Category | MUMPC | 1.0 | Reference | - | - |
| IMPC vs MUMPC | 1.2 (0.2–6.9) | .87 | - | - | |
| IDMPC vs MUMPC | 1.4 (0.2–8.4) | .71 | - | - | |
| NG | 2.5 (0.7–8.7) | .15 | - | - | |
| Mitosis | 1.9 (0.8–4.1) | .13 | - | - | |
| ER | 0.3 (0.1–1.2) | .09 | - | - | |
| PR | 0.2 (0.1–0.7) | .02 | 0.7 (0.1–6.6) | .78 | |
| HER2 | 7.3 (1.6–33.0) | .01 | 1.1 (0.1–11) | .92 | |
| Ki-67 | 4.2 (0.5–36.0) | .19 | - | - | |
| MS | LA | 1.0 | Reference | - | - |
| LB vs LA | 0.0 | .10 | - | - | |
| HER2 vs LA | 4.8 (0.6–41.0) | .15 | - | - | |
| Basal-like vs LA | 1.2 (0.1–13.0) | .88 | - | - | |
| T-stage | 15 (3.2–72.0) | .001 | 14 (2.1–88) | .006 | |
| LNM | 15 (1.8–130.0) | .01 | 9 (0.6–149) | .11 |
RR, relative risk; 95% CI, 95% confidence interval; MUMPC, mucinous carcinoma with micropapillary feature; IMPC, invasive micropapillary carcinoma; IDMPC, mixed invasive ductal and micropapillary carcinoma; NG, nuclear grade; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; MS, molecular subtype; LA, luminal A; LB, luminal B; LNM, lymph node metastasis.